Week In Review: Korea's Hanmi Signs $4.2 Billion Deal With Sanofi

Tsinghua University has started a Medical Big Data Center at its Center for Statistical Science (see story). The center was established in response to the call of the State Council of China for big data research. Earlier this week, Dr. Jun Wang, formerly of BGI, announced another big data healthcare-focused company, iCarbonX. Although there will be overlap, iCarbonX seems to emphasize biologic research while the Tsinghua Center is more concerned with clinical decision making. 

JHL Biotech, a Taiwan-China biopharma, built a biologics CMO facility in Wuhan in just 11 days, using modular components fabricated in Germany (see story). General Electric constructed the components, which it calls a KUBio™ modular factory. JHL already has a biosimilars manufacturing facility in Taiwan, but chose the GE kit for its Wuhan location because the company believes a prefabricated plant will speed up CFDA and international audits of the facility.  

Trials and Approvals

Akers Biosciences (NSDQ: AKER; AIM:AKR.L) of the US received CFDA approval of its diagnostic test for allergic reactions to heparin, the blood thinner (see story). Akers' PIFA Heparin/PF4 Rapid Assay (and the whole blood PIFA PLUSS PF4 version) test for PF4 antibodies, which are associated with heparin-induced thrombocytopenia (HIT). The Akers diagnostic is the first test for the condition approved in China. NovoTek of Beijing will be in charge of China distribution. 

1 2 3
View single page >> |

Disclosure: ChinaBio® ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.